Phase 2a trial of Jotrol for Parkinson’s begins enrolling patients in the U.S.
Experimental treatment's safety, tolerability will be assessed
Written by |
- A Phase 2a trial of Jotrol is enrolling Parkinson's disease patients.
- Jotrol aims to reduce brain inflammation and oxidative stress.
- The trial will assess Jotrol's safety, tolerability, and effects on motor/non-motor symptoms.
Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by Jupiter Neurosciences as a treatment for Parkinson’s disease, the company has announced.
The RESET trial (NCT07592767) is recruiting up to 30 patients at three sites in the U.S.: Georgetown University MedStar Hospital in Washington, DC; Montgomery and Franklin Square MedStar Hospitals in Maryland; and MedStar McLean Clinic in Virginia.
The trial, which will assess the treatment’s safety, tolerability, and pharmacological properties, is expected to be completed in the first half of 2027.
“With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL’s potential and to serve patients, providers, and the broader scientific community,” Christer Rosén, Jupiter’s CEO, said in a company press release.
Jotrol preserved motor function in mouse model
Parkinson’s is marked by the loss of brain cells called dopaminergic neurons, which produce dopamine, a signaling molecule involved in motor control. Lack of dopamine signaling leads to the disease’s symptoms, including movement problems and cognitive issues.
While the exact causes of Parkinson’s aren’t fully known, research suggests that excessive brain inflammation and oxidative stress, a type of cellular damage, help drive nerve cell damage and contribute to disease progression.
Resveratrol is a compound found in certain plants, including grapes, with anti-inflammatory and antioxidant properties, meaning it can reduce inflammation and oxidative stress. However, its use has been limited due to digestive issues when taken orally at high doses.
Jotrol is a micellar formulation in which resveratrol is dissolved as a soft gel that can be taken as an oral capsule. It can cross the blood-brain barrier, a tight layer of cells lining the brain’s blood vessels that prevents certain molecules from entering the brain, allowing it to reach the brain and potentially treat Parkinson’s and other neurological diseases.
The treatment was found to preserve motor function in a mouse model of Parkinson’s. Results from a Phase 1 trial (NCT04668274) testing the treatment in healthy volunteers have shown that Jotrol has nine times higher bioavailability (the ability to be used by the body) than traditional resveratrol oral formulations and can deliver a therapeutic dose without gastrointestinal side effects.
We believe JOTROL’s enhanced [central nervous system] exposure and mechanistic profile position it as a potentially differentiated therapeutic candidate for neurodegenerative disorders.
These data supported clearance from the U.S. Food and Drug Administration to start testing Jotrol in people with Parkinson’s disease, which was granted in November 2025.
“Despite advances in symptomatic management, there remains a significant unmet need for therapies that may address the underlying biological drivers of Parkinson’s disease,” said Charbel Moussa, PhD, professor at Georgetown University Medical Center and coordinating principal investigator of the RESET study. “We believe JOTROL’s enhanced [central nervous system] exposure and mechanistic profile position it as a potentially differentiated therapeutic candidate for neurodegenerative disorders.”
The RESET study is enrolling people with moderate Parkinson’s disease, ages 55 to 85 years, without severe cognitive impairment. They must be stable on levodopa or dopamine agonists — medications commonly used to treat the disease symptoms — for at least four weeks before entering the study.
Participants will be randomly assigned to receive one of two doses of Jotrol (200 mg or 400 mg) or a placebo once daily for 12 weeks (about three months). The main goal is to assess the treatment’s safety and tolerable dose in the blood and cerebrospinal fluid (CSF), which surrounds the brain and spinal cord.
Secondary outcomes include evaluation of biomarkers of inflammation in the brain and CSF, and effects of Jotrol on motor and nonmotor symptoms of Parkinson’s, behavioral and cognitive symptoms, and health-related quality of life.
Leave a comment
Fill in the required fields to post. Your email address will not be published.